Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PCSK9 is a serine protease that acts as a negative regulator of hepatic clearance of plasma cholesterol by promoting lysosomal degradation rather than recycling of cell-surface LDL receptors—a process central to cholesterol homeostasis. Blockade or genetic disruption reduces plasma levels of atherogenic lipoproteins and lowers cardiovascular risk.
Block PCSK9 interaction with LDLR, preventing LDLR degradation and increasing LDL-C clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proprotein convertase subtilisin/kexin type 9 (PCSK9).